Der Internist

, Volume 46, Issue 5, pp 586–591 | Cite as

Pharmakotherapie chronisch entzündlicher Darmerkrankungen

Hoffnungen, Enttäuschungen
Arzneimitteltherapie
  • 62 Downloads

Zusammenfassung

Die Ätiologie chronisch entzündlicher Darmerkrankungen ist unklar. Während die Therapie der ursächlichen Störung nicht möglich scheint, bietet die Pathophysiologie der intestinalen Entzündung zahlreiche Interventionsmöglichkeiten. Ziel ist die langfristige Therapie der Erkrankung und damit eine Beeinflussung des chronischen Krankheitsverlaufs. Die pharmakotherapeutischen Möglichkeiten schließen 5-Aminosalizylate, Glukokortikoide, Immunsuppressiva (Azathioprin, Methotrexat) sowie spezifische Eingriffe in das Immunsystem (monoklonale Antikörper gegen TNF-α) ein. Wichtige supportive Therapieverfahren sind geeignet, die Symptomatik (Schmerzen, Diarrhö) zu beeinflussen. Der Einsatz ernährungstherapeutischer und chirurgischer Verfahren stellt eine wichtige Alternative oder Ergänzung zu pharmakotherapeutischen Interventionen dar.

Schlüsselwörter

Chronisch-entzündliche Darmerkrankungen Morbus Crohn Colitis ulcerosa Immunsupressiva 5-Aminosalizylate Glukokortikoide 

Therapy of inflammatory bowel diseases

Abstract

Because the etiology of inflammatory bowel diseases is unclear, no causative therapy is available. However, pathophysiology of the disease offers a lot of possibilities to disrupt the inflammatory cascade that maintains the inflammatory process. The aim of every therapy is to maintain remission as long as possible and to amend the natural course of the disease. Pharmacotherapy includes 5-Aminosalicylates, glucocorticoids, immunosupressants (methotrexate, azathioprine) as well as specific pharmacologic interventions like monoclonal antibodies directed against TNF-alpha (Infliximab). Important supportive tools are available to improve symptoms like diarrhea and pain. Dietetic treatment and surgical procedures represent important alternatives or supplement pharmacotherapeutic interventions.

Keywords

Inflammatory bowel diseases 5-Aminosalicylates Immunosupressants Glucocorticoids 

Literatur

  1. 1.
    Azad Khan AK, Piris J, Truelove SC (1977) An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2: 892–895Google Scholar
  2. 2.
    Bouhnik Y, Lémann M, Mary JY et al. (1996) Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 347: 215–219Google Scholar
  3. 3.
    Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R (1995) A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 37: 674–678PubMedGoogle Scholar
  4. 4.
    Egan LJ, Sandborn WJ, Tremaine WJ et al. (1999) A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther 13: 1597–1604Google Scholar
  5. 5.
    Feagan BG, McDonald JWD, Rochon J et al. (1994) Low dose cyclosporine for the treatment of Crohn’s disease. N Engl J Med 330: 1846–1851Google Scholar
  6. 6.
    Feagan BG, Rochon J, Fedorak RN et al. (1995) Methotrexate for the treatment of Crohn’s disease. N Engl J Med 332: 292–297Google Scholar
  7. 7.
    Feagan BG, Fedorak RN, Irvine EJ et al. (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 342: 1627–1632CrossRefPubMedGoogle Scholar
  8. 8.
    Fedorak RN, Gangl A, Elson CO et al. (2000) Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. Gastroenterology 119: 1473–1482Google Scholar
  9. 9.
    Gionchetti P, Rizzello F, Venturi A et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305–309PubMedGoogle Scholar
  10. 10.
    Graham DY, Al-Assi MT, Robinson M (1995) Prolonged remission in Crohn’s disease following therapy for mycobacterium paratuberculosis infection. Gastroenterology 108: A826Google Scholar
  11. 11.
    Greenberg GR, Feagan BG, Martin F et al. (1994) Oral budesonide for active Crohn’s disease. Canadian inflammatory bowel disease Study Group. N Engl J Med 331: 836–841CrossRefPubMedGoogle Scholar
  12. 12.
    Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11: 853–858Google Scholar
  13. 13.
    Lichtiger S, Present DH, Kronbluth A et al. (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330: 1841–1845CrossRefPubMedGoogle Scholar
  14. 14.
    Lochs H, Steinhardt HJ, Klaus-Wentz B, Vogelsang H, Sommer H (1991) Comparison of enteral nutrition and drug treatment in active Crohn’s disease Gastroenterology 101: 881–888Google Scholar
  15. 15.
    Lofberg R, Rutgeerts P, Malchow H et al. (1996) Budesonide prolongs time to relapse in ileal and ileocaecal Crohn’s disease: a placebo controlled one year study. Gut 39: 82–86Google Scholar
  16. 16.
    Lorenz-Meyer H, Bauer P, Nicolay C et al.; Study Group Members (German Crohn’s disease study group) (1996) Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn’s disease. Scand J Gastroenterol 31: 778–785Google Scholar
  17. 17.
    Malchow H, Ewe K, Brandes JW et al. (1984) European cooperative Crohn’s disease study (ECCDS): Results of drug treatment. Gastroenterology 86: 249–266PubMedGoogle Scholar
  18. 18.
    Marshall JK, Irvine EJ (1997) Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40: 775–781Google Scholar
  19. 19.
    Miglioli M, Bianchi P, Brunetti G, Sturniolo GC and the Italian IBD group (1990) Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. Eur J Gastroenterology 2: 229–234Google Scholar
  20. 20.
    Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E (1990) Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98: 811–818PubMedGoogle Scholar
  21. 21.
    Nikolaus S, Raedler A, Kühbacher T, Sfikas N, Fölsch UR, Schreiber S (2000) Mechanisms in failure of infliximab for Crohn’s disease. Lancet 356: 1475–1479Google Scholar
  22. 22.
    Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-Mercaptopurine in Crohn’s disease. Ann Internal Med 123: 132–142Google Scholar
  23. 23.
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS (1980) Treatment of Crohn’s disease with 6-mercatopurine. A long-term, randomized, double-blind study. N Engl J Med 302: 981–987PubMedGoogle Scholar
  24. 24.
    Present DH, Rutgeerts P, Targan S et al. (1999) Infliximab for the treatment of fistula in patients with Crohn’s disease. N Engl J Med 340: 1398–1405CrossRefPubMedGoogle Scholar
  25. 25.
    Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635–639Google Scholar
  26. 26.
    Riordan AM, Hunter JO, Cowan JR, Crampton JR, Davidson AR, Dickinson RJ (1993) Treatment of active Crohn’s disease by exclusion diet: East Anglican multicentre controlled trial. Gut 342: 1131–1134Google Scholar
  27. 27.
    Rutgeerts P, Lofberg R, Malchow H et al. (1994) A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 331: 842–845CrossRefPubMedGoogle Scholar
  28. 28.
    Rutgeerts P, Hiele M, Geboes K et al. (1995) Controlled trial of metronidazole treatment for prevention of Crohn’s reoccurence after ileal resection. Gastroenterology 108: 1617–1621PubMedGoogle Scholar
  29. 29.
    Rutgeerts P, D’Haens G, Targan S et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117: 761–769PubMedGoogle Scholar
  30. 30.
    Schreiber S, Howaldt S, Schnoor M et al. (1996) Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 334: 619–623Google Scholar
  31. 31.
    Schreiber S, Fedorak RN, Nielsen OH et al. (2000) Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Gastroenterology 119: 1461–1472Google Scholar
  32. 32.
    Schreiber S, Nikolaus S, Malchow H et al. and the German ICAM-1 study group (2001) Absence of efficacy of subcutaneous Anti-sense ICAM-1 for treatment of Chronic active Crohn’s Disease. Gastroenterology 120: 1339–1346Google Scholar
  33. 33.
    Singleton JW, Hanauer SB, Gitnick GL et al. and the PENTASA Crohn’s disease study group (1993) Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Gastroenterology 104: 1291–1301Google Scholar
  34. 34.
    Stange EF, Modigliani R, Pena AS, Wood AJ, Feutren G, Smith PR and the European study group (1995) European trial of cyclosporine in chronic active Crohn’s disease: A 12-month study. Gastroenterology 109: 774–782Google Scholar
  35. 35.
    Summers RW, Switz DM, Sessions JT et al. (1979) National cooperative Crohn’s disease Study: Results of drug treatment. Gastroenterology 77: 847–869Google Scholar
  36. 36.
    Targan SR, Hanauer SB, van Deventer SJH et al. (1997) A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn’s disease. N Engl J Med 337: 1029–1035CrossRefPubMedGoogle Scholar
  37. 37.
    Ursing B, Alm T, Barany F et al. (1982) A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the Cooperative Crohn’s disease study in Sweden II. Result. Gastroenterology 83: 550–562Google Scholar
  38. 38.
    Weber CK, Liptay S, Wirth T, Adler G, Schmid RM (2000) Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119: 1209–1218Google Scholar
  39. 39.
    Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR (1998) A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease. Gastroenterology 114: 1133–1142Google Scholar

Copyright information

© Springer Medizin Verlag 2005

Authors and Affiliations

  1. 1.Klinik für Allgemeine Innere Medizin, 1. Medizinische KlinikCampus Kiel des Universitätsklinikums Schleswig-Holstein
  2. 2.1. Medizinische KlinikUniversitätsklinik Schleswig-HolsteinKiel

Personalised recommendations